reports
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Re...
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025, at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today...
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MIMEDX Announces Strategic Collaboration with Vaporox, Inc. Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights re...
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Con...
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30 MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Web...
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY...
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026 New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse MARIETTA, Ga., July 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) proposal. “We welcome and support improvements to Medicare’s reimbursement of skin substitutes across all care settings. The proposed rule, which was published yesterday afternoon, ...
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual1:1 sessions: Wednesday, June 25, 2025 Investors int...
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. Presentation Details: Tuesday, May 13, 20255:15 p.m. PDT Investors interested in meeting with senior management at this event may contact their Bank of America representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade ...
MIMEDX Announces Publication of Health Economics Data in Mohs Microgra...
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS) Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company’s EPIFIX® Placental Allograft Product MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology...
MIMEDX Announces First Quarter 2025 Operating and Financial Results
MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operati...
MIMEDX to Host First Quarter 2025 Operating and Financial Results Conf...
MIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30 MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: ...
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at ...
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. “MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of scientific and clinical evidence will be on ful...
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects o...
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Finan...
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and fu...
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financi...
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26 MARIETTA, Ga., Feb. 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2024 after the market close on Wednesday, February 26, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be access...
MIMEDX Files Patent Infringement Lawsuit Against Surgenex
MIMEDX Files Patent Infringement Lawsuit Against Surgenex Company Set to Defend Its Extensive IP Catalog for Leading Placental Allografts MARIETTA, Ga., Dec. 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has filed a lawsuit against Surgenex, LLC in the United States District Court for the District of Arizona. The complaint asserts that several of Surgenex’s placental allograft products infringe the Company’s patents and seeks permanent injunctive relief and monetary damages. This matter represents the second lawsuit by...
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Dec. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Mizuho Health Care ConferenceWednesday, December 11, 20241:1 sessions | New York, NY Northland Growth ConferenceThursday, December 12, 20241:1 sessions | Virtual Stifel MedTech West Coast Bus TourThursday, December 12, 20241:1 sessions | Palo Alto, CA Investors interested in meeting with senior management at these...
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitut...
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs’ Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabeti...
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Stifel Healthcare Conference 2024Webcast (9:45 AM ET): Monday, November 18, 2024New York, NY 15th Annual Craig-Hallum Alpha Select ConferenceTuesday, November 19, 2024New York, NY Investors interested in meeting with senior management at these events may contact their respective Stifel or Craig-Hallum representativ...
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
MIMEDX Announces Third Quarter 2024 Operating and Financial Results Net Sales of $84 million Grew 3% Year-Over-Year for the Third QuarterThird Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, RespectivelyThird Quarter Adjusted EBITDA was $18 Million, or 22% of Net SalesRaises 2024 Net Sales Growth Expectations to the High Single-DigitsManagement to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial result...
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conf...
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30 MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following informat...
MIMEDX Points to The New York Times Article on the Vast Benefits of Pl...
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue Story Featured Patients Treated with MIMEDX Products MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today’s New York Times: “Her Face Was Unrecognizable After an Explosion. A Placenta Restored It.” The author underscored the benefits of placental allografts for a variety of wound ca...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.